JAK-STAT pathway

JAK-STAT Pathway - Cytokine Superhighway

• Receptors: Use non-receptor tyrosine kinases (Janus Kinases - JAKs).
• Ligands: Prolactin, Immunomodulators (e.g., Cytokines, IL-2, IFN), Growth Hormone, Erythropoietin (EPO), Thrombopoietin (TPO). 📌 Mnemonic: "PIGGLET"
• Function: Essential for hematopoiesis, immune response, and inflammation.

⭐ A gain-of-function mutation in JAK2 (V617F) is a key driver in myeloproliferative neoplasms, especially Polycythemia Vera.

• Inhibitors: Ruxolitinib (JAK1/2 inhibitor) is used to treat myelofibrosis.

Key Components - The JAK & STAT Families

• Janus Kinases (JAKs): Intracellular, non-receptor tyrosine kinases that associate with cytokine receptors. Think of them as the gatekeepers.

  • Four members: JAK1, JAK2, JAK3, & TYK2.
  • They get activated upon receptor-ligand binding.

• Signal Transducers and Activators of Transcription (STATs): Latent cytoplasmic transcription factors.

  • Seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, & STAT6.
  • Function: Once phosphorylated by JAKs, they dimerize, move to the nucleus, and regulate gene transcription.

⭐ High-Yield: Mutations in JAK2 (specifically the V617F mutation) are a classic finding in myeloproliferative neoplasms, especially Polycythemia Vera.

Regulation - Negative Feedback Loops

• SOCS (Suppressor of Cytokine Signaling): Key negative regulators. STAT activation induces SOCS gene transcription, creating a feedback loop. SOCS proteins then inhibit JAK activity or target components for proteasomal degradation.
• PIAS (Protein Inhibitor of Activated STAT): Block STAT DNA-binding activity.
• PTPs (Protein Tyrosine Phosphatases): E.g., SHP-1; dephosphorylate and inactivate JAKs and STATs.

⭐ In myeloproliferative neoplasms, JAK2 mutations cause constitutive activation, bypassing these negative feedback controls and leading to uncontrolled cell growth.

Clinical Correlations - Pathologic Signaling

• Gain-of-Function (GOF) Mutations:
  • Constitutively activate JAKs, leading to myeloproliferative neoplasms (MPNs).
  • 📌 Primary myelofibrosis, Vera (polycythemia), Thrombocythemia (essential).
  • Common mutation: JAK2 V617F.
• Loss-of-Function (LOF) Mutations:
  • Lead to immunodeficiencies by impairing cytokine responses.
  • Example: Autosomal Dominant Hyper-IgE Syndrome (Job Syndrome) from STAT3 mutations → recurrent infections, eczema.
• Therapeutic Targeting:
  • JAK inhibitors ("-tinibs" e.g., Ruxolitinib, Tofacitinib) treat MPNs and inflammatory conditions like rheumatoid arthritis.

⭐ The JAK2 V617F mutation is present in >95% of patients with polycythemia vera, making it a key diagnostic marker.

High‑Yield Points - ⚡ Biggest Takeaways

• The JAK-STAT pathway is a primary signaling cascade for cytokines, interferons, and growth factors.
• It operates via non-receptor tyrosine kinases called Janus kinases (JAKs).
• Ligand binding causes receptor dimerization, activating JAKs to autophosphorylate and phosphorylate the receptor.
• STAT proteins are recruited, phosphorylated by JAKs, and then dimerize.
• These STAT dimers translocate to the nucleus, acting as transcription factors.
• Dysregulation is central to myeloproliferative neoplasms and many autoimmune diseases.
• JAK inhibitors (e.g., Ruxolitinib) are crucial targeted therapies.